Novocure's Optune Pax Receives CE Mark for Pancreatic Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Novocure announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. "Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival rates have remained low for decades. However, in the Phase 3 PANOVA-3 trial for Optune Pax, a statistically significant improvement in overall survival was observed in patients who were at an advanced stage of disease," said Teresa Macarulla, MD, PhD, Head of the Department of Medical Oncology at Hospital Clinic Barcelona. "In addition, Optune Pax was also shown to delay pain progression, a debilitating symptom of pancreatic cancer. This is a promising treatment for patients who have an urgent need for new options."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCR
Wall Street analysts forecast NVCR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 17.720
Low
13.50
Averages
23.58
High
39.00
Current: 17.720
Low
13.50
Averages
23.58
High
39.00
About NVCR
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovoCure Under Investigation for Possible Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether NovoCure Limited has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Disappointing Clinical Trial Results: On June 18, 2026, NovoCure announced that its TRIDENT trial did not show a statistically significant improvement in overall survival for the Early Start Arm compared to the Maintenance Start Arm, potentially impacting its market outlook.
- Significant Stock Price Drop: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share, reflecting market concerns about the company's future prospects.
- Investor Contact Information: Pomerantz LLP advises investors to contact Danielle Peyton for inquiries, highlighting the firm's commitment to protecting investor rights.
See More
NovoCure Under Investigation for Possible Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating NovoCure Limited and its executives for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Clinical Trial Results: On June 18, 2026, NovoCure announced that its TRIDENT trial results indicated that early initiation of Tumor Treating Fields (TTFields) therapy did not show a statistically significant improvement in overall survival compared to later initiation, potentially affecting market acceptance of its future treatment protocols.
- Stock Price Plunge: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share, reflecting market concerns regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against NovoCure, and if fraud is confirmed, it could severely impact the company's reputation and financial health, prompting investors to closely monitor further developments.
See More
NovoCure Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating NovoCure Limited and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and pursue legal accountability.
- Clinical Trial Results: On June 18, 2026, NovoCure announced that its Phase 3 TRIDENT trial failed to show a statistically significant improvement in overall survival for the Early Start Arm compared to the Maintenance Start Arm, which may impact the company's future treatment strategies.
- Stock Price Plunge: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share on June 18, 2026, reflecting market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation with a long history of recovering multimillion-dollar damages for victims, indicates that this investigation could lead to significant legal and financial risks for NovoCure.
See More
Investment Choices Between HeartFlow and NovoCure: Diagnostics vs. Therapeutics
- HeartFlow's Diagnostic Technology: HeartFlow employs AI for non-invasive diagnosis of coronary artery disease, achieving approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite reporting a net loss of $116.8 million, highlighting a tension between market expansion potential and profitability.
- Cancer Treatment Innovation: NovoCure's Tumor Treating Fields therapy generated about $655.4 million in revenue for FY 2025, an 8.3% increase, yet it also faced a net loss of nearly $136.2 million, indicating ongoing pressure from significant investments in its clinical pipeline.
- Risks and Challenges: HeartFlow's revenue is heavily concentrated, with 98% coming from its core diagnostic tool, and it is currently under a Civil Investigative Demand from the DOJ and facing patent litigation, which could impact future revenues; meanwhile, NovoCure's reliance on its Optune products exposes it to regulatory risks and collaboration risks with Zai Lab.
- Market Outlook Comparison: Although neither company is profitable, NovoCure's projected revenue of $704 million for FY 2026 significantly surpasses HeartFlow's $230 million, and its lower price-to-sales ratio presents a relative bargain, making NovoCure a more attractive option for long-term investors.
See More
Investment Comparison Between NovoCure and Omeros
- NovoCure's Market Performance: NovoCure reported nearly $655.4 million in FY 2025 revenue, an 8.3% increase year-over-year, despite facing a net loss of approximately $136.2 million, indicating high costs associated with market expansion.
- Omeros's Product Launch: Omeros received FDA approval for Yartemlea in late 2025, with first-quarter sales reaching $9.89 million, reflecting strong market interest, and is projected to generate $68 million in revenue for 2026, showcasing its potential for commercial transition.
- Risk Analysis: NovoCure's heavy reliance on Optune Gio for revenue poses risks if it fails to expand into new markets or faces changes in Medicare policies, while Omeros's success hinges on the market acceptance of Yartemlea and its dependence on Novo Nordisk for development.
- Valuation Comparison: NovoCure appears significantly cheaper with a P/S ratio of 2.4 compared to Omeros's 74.3, indicating a higher market valuation for Omeros despite profitability not being expected until 2028 and beyond.
See More
Comparing Investment Prospects of Amgen and NovoCure
- Amgen's Financial Performance: In FY 2025, Amgen's revenue reached $36.8 billion, reflecting a 10.1% growth with a net income of $7.7 billion, showcasing its strong market position in chronic disease treatments, although high customer concentration poses risks.
- NovoCure's Unique Model: NovoCure generated approximately $655.4 million in FY 2025, an 8.3% increase, but reported a net loss of nearly $136.2 million, highlighting the high costs associated with expanding its product reach.
- Debt and Cash Flow: Amgen's debt-to-equity ratio stands at 6.3x, indicating heavy reliance on borrowed funds, yet it generated $8.1 billion in free cash flow, demonstrating robust cash generation; in contrast, NovoCure's ratio is 0.9x with negative free cash flow of $75.7 million, indicating significant funding needs.
- Market Competition and Outlook: Amgen faces regulatory pressures, particularly from the Inflation Reduction Act, while NovoCure relies on stringent regulatory approvals and payer coverage, with its core product recently FDA-approved, yet future growth potential appears limited.
See More
NovoCure Under Investigation for Possible Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether NovoCure Limited has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Disappointing Clinical Trial Results: On June 18, 2026, NovoCure announced that its TRIDENT trial did not show a statistically significant improvement in overall survival for the Early Start Arm compared to the Maintenance Start Arm, potentially impacting its market outlook.
- Significant Stock Price Drop: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share, reflecting market concerns about the company's future prospects.
- Investor Contact Information: Pomerantz LLP advises investors to contact Danielle Peyton for inquiries, highlighting the firm's commitment to protecting investor rights.
See More
NovoCure Under Investigation for Possible Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating NovoCure Limited and its executives for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Clinical Trial Results: On June 18, 2026, NovoCure announced that its TRIDENT trial results indicated that early initiation of Tumor Treating Fields (TTFields) therapy did not show a statistically significant improvement in overall survival compared to later initiation, potentially affecting market acceptance of its future treatment protocols.
- Stock Price Plunge: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share, reflecting market concerns regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against NovoCure, and if fraud is confirmed, it could severely impact the company's reputation and financial health, prompting investors to closely monitor further developments.
See More
NovoCure Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating NovoCure Limited and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and pursue legal accountability.
- Clinical Trial Results: On June 18, 2026, NovoCure announced that its Phase 3 TRIDENT trial failed to show a statistically significant improvement in overall survival for the Early Start Arm compared to the Maintenance Start Arm, which may impact the company's future treatment strategies.
- Stock Price Plunge: Following the disappointing trial results, NovoCure's stock price fell by $3.57, or 20%, closing at $14.28 per share on June 18, 2026, reflecting market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation with a long history of recovering multimillion-dollar damages for victims, indicates that this investigation could lead to significant legal and financial risks for NovoCure.
See More
Investment Choices Between HeartFlow and NovoCure: Diagnostics vs. Therapeutics
- HeartFlow's Diagnostic Technology: HeartFlow employs AI for non-invasive diagnosis of coronary artery disease, achieving approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite reporting a net loss of $116.8 million, highlighting a tension between market expansion potential and profitability.
- Cancer Treatment Innovation: NovoCure's Tumor Treating Fields therapy generated about $655.4 million in revenue for FY 2025, an 8.3% increase, yet it also faced a net loss of nearly $136.2 million, indicating ongoing pressure from significant investments in its clinical pipeline.
- Risks and Challenges: HeartFlow's revenue is heavily concentrated, with 98% coming from its core diagnostic tool, and it is currently under a Civil Investigative Demand from the DOJ and facing patent litigation, which could impact future revenues; meanwhile, NovoCure's reliance on its Optune products exposes it to regulatory risks and collaboration risks with Zai Lab.
- Market Outlook Comparison: Although neither company is profitable, NovoCure's projected revenue of $704 million for FY 2026 significantly surpasses HeartFlow's $230 million, and its lower price-to-sales ratio presents a relative bargain, making NovoCure a more attractive option for long-term investors.
See More
Investment Comparison Between NovoCure and Omeros
- NovoCure's Market Performance: NovoCure reported nearly $655.4 million in FY 2025 revenue, an 8.3% increase year-over-year, despite facing a net loss of approximately $136.2 million, indicating high costs associated with market expansion.
- Omeros's Product Launch: Omeros received FDA approval for Yartemlea in late 2025, with first-quarter sales reaching $9.89 million, reflecting strong market interest, and is projected to generate $68 million in revenue for 2026, showcasing its potential for commercial transition.
- Risk Analysis: NovoCure's heavy reliance on Optune Gio for revenue poses risks if it fails to expand into new markets or faces changes in Medicare policies, while Omeros's success hinges on the market acceptance of Yartemlea and its dependence on Novo Nordisk for development.
- Valuation Comparison: NovoCure appears significantly cheaper with a P/S ratio of 2.4 compared to Omeros's 74.3, indicating a higher market valuation for Omeros despite profitability not being expected until 2028 and beyond.
See More
Comparing Investment Prospects of Amgen and NovoCure
- Amgen's Financial Performance: In FY 2025, Amgen's revenue reached $36.8 billion, reflecting a 10.1% growth with a net income of $7.7 billion, showcasing its strong market position in chronic disease treatments, although high customer concentration poses risks.
- NovoCure's Unique Model: NovoCure generated approximately $655.4 million in FY 2025, an 8.3% increase, but reported a net loss of nearly $136.2 million, highlighting the high costs associated with expanding its product reach.
- Debt and Cash Flow: Amgen's debt-to-equity ratio stands at 6.3x, indicating heavy reliance on borrowed funds, yet it generated $8.1 billion in free cash flow, demonstrating robust cash generation; in contrast, NovoCure's ratio is 0.9x with negative free cash flow of $75.7 million, indicating significant funding needs.
- Market Competition and Outlook: Amgen faces regulatory pressures, particularly from the Inflation Reduction Act, while NovoCure relies on stringent regulatory approvals and payer coverage, with its core product recently FDA-approved, yet future growth potential appears limited.
See More
